Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
COAST
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
- NCT03822351 ↗
- Completed
- MedImmune LLC
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on COAST yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on COAST so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Stage III Non-small Cell Lung Cancer; Unresectable
- Interventions
- Durvalumab + Oleclumab; Durvalumab; Durvalumab + Monalizumab
- Arms
- Control Arm (Durvalumab monotherapy) · Experimental
- Arm A (durvalumab + oleclumab): · Experimental
- Arm B (durvalumab + monalizumab) · Experimental
- Enrollment
- 189
- Primary outcomes
- Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
- Sponsor
- MedImmune LLC
- Start
- Dec 19, 2018
- Primary completion
- Jul 18, 2023
- Results posted
- Yes
- Registry record
- NCT03822351 · updated Oct 8, 2024
Publications
linked from the registry- Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Pillet M, Brown M, Paliompeis C, Dowson A, Cooper ZA, Kumar R, Herbst RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial. JAMA Netw Open. 2025 Jul 1;8(7):e2518440. doi: 10.1001/jamanetworkopen.2025.18440. PubMed 40663352
- Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Oct 10;40(29):3383-3393. doi: 10.1200/JCO.22.00227. Epub 2022 Apr 22. PubMed 35452273